Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

The Dow Jones Industrial Average rose 317.24 points, or 0.71%, to 44,873.28, the S&P 500 rose 23.60 points, or 0.39%, to ...

"We think the leaders of other countries don't really understand Trump's art of the deal," said Jay Hatfield, CEO and ...

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Wall Street struggled for direction and benchmark Treasury yields slid on Wednesday as disappointing earnings and mixed economic data counterbalanced easing ...

Iván Romeo secured his first professional victory racing for Movistar with a solo win on stage 3 at the Volta a la Comunitat ...